ZYME Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (25 Apr 2024 @ 16:00):

Stats
Today's Volume	410 965
Average Volume	574 061
Market Cap	572.31M
EPS	$0 ( 2024-03-06 )
Next earnings date	( $-0.310 ) 2024-05-02
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.72
ATR14	$0.0100 (0.12%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-02	Gallagher Neil	Buy	74 000	Stock Option (Right to Buy)
2024-04-02	Gallagher Neil	Sell	0	No securities are beneficially owned
2024-02-22	Platshon Scott	Buy	0
2024-02-08	Cesano Alessandra	Buy	74 000	Stock Option (Right to Buy)
2024-02-08	Cesano Alessandra	Sell	0	No securities are beneficially owned

INSIDER POWER
94.07
Last 71 transactions
Buy: 13 173 358 \| Sell: 322 010

Volume Correlation

Long: -0.32 (neutral)

Short: 0.95 (very strong)

Signal:(49.029) Expect same movement, but be aware

Zymeworks Inc Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Zymeworks Inc Correlation - Currency/Commodity

-0.22
( neutral )

-0.51
( weak negative )

0.00
( neutral )

-0.65
( moderate negative )

0.44
( neutral )

-0.75
( moderate negative )

Zymeworks Inc Financials

Annual	2023
Revenue:	$76.01M
Gross Profit:	$-66.98M (-88.11 %)
EPS:	$-1.720

Q4	2023
Revenue:	$16.93M
Gross Profit:	$-8.30M (-49.03 %)
EPS:	$-0.200

Q3	2023
Revenue:	$16.51M
Gross Profit:	$-16.44M (-99.58 %)
EPS:	$-0.410

Q2	2023
Revenue:	$7.00M
Gross Profit:	$-32.41M (-462.81 %)
EPS:	$-0.760

Financial Reports:

No articles found.

Zymeworks Inc

Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.